Xcell Biosciences
VerifiedBuilding products that enable propagation and gene editing in challenging cell types for clinical research and cell therapy applications.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$110—165m (Dealroom.co estimates Jan 2022.)
San Francisco California (HQ)
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | $0.0 | round |
| N/A | $0.0 | round | |
| investor investor investor | $0.0 | round | |
| investor investor | $0.0 | round | |
| N/A | $0.0 | round | |
| investor investor investor investor investor investor | $0.0 | round | |
* | N/A | Late VC | |
| Total Funding | 000k | ||
Related Content
Recent News about Xcell Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.